A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers Article

Industry Collaboration

cited authors

  • Bendell, Johanna C., Zakari, Ahmed, Lang, Evan, Waterhouse, David, Flora, Douglas, Alguire, Kathryn, McCleod, Michael, Peacock, Nancy, Ruehlman, Peter, Lane, Cassie M., Earwood, Chris, Shih, Kent

funding text

  • Consultancy- money paid to self-BMS-ongoing Payment for lectures including service on speakers bureaus-money paid to self-BMS; Lilly-ongoing Payment for development of educational presentations-money paid to self-Genentech-past

abstract

  • Purpose: To evaluate efficacy and safety of bevacizumab, pertuzumab, and octreotide depot for advanced neuroendocrine tumors.Methods: Patients received bevacizumab 15mg/kg and pertuzumab 420mg IV q21days with octreotide depot 30mg IM q28days.Results: Toxicities in 43 patients included diarrhea (63%), fatigue (63%), hypertension (44%), and nausea (44%). Reversible G3 hypertension (26%) and LVEF decline (9%) occurred. 7/43 patients achieved objective response (typical carcinoid, 5; pancreatic NET, 2). Median PFS and OS were 6.5 and 26.4months, respectively.Discussion: Bevacizumab, pertuzumab, and octreotide depot was well-tolerated with a 16% ORR. Results in the well-differentiated carcinoid tumors are thought provoking.

Publication Date

  • January 1, 2016

webpage

published in

category

start page

  • 213

end page

  • 219

volume

  • 34

issue

  • 5

WoS Citations

  • 4

WoS References

  • 15